More accurate risk assessment developed for Alzheimer's disease among nonwhite patients

Researchers have developed improved methods for assessing Alzheimer's disease risk in nonwhite populations, addressing significant disparities in clinical risk prediction. Late-onset Alzheimer's, which affects approximately 6.9 million Americans, is a progressive neurodegenerative disorder marked by cognitive decline and memory loss that can take years to develop. Genetic factors play a central role in determining both the onset and progression of cognitive deterioration, yet previous risk assessment tools were not equally accurate across racial and ethnic groups. This advancement in risk stratification could enable earlier detection and more personalized treatment approaches for diverse patient populations, helping to reduce health inequities in Alzheimer's care and research.